1stOncology™: Cancer Intelligence Service – Page 109 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Supernus Pharmaceuticals to Participate in June Investor Conferences

On May 27, 2026 Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, reported that management will participate in the following June investor conferences:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

2026 Jefferies Global Healthcare Conference
Date:
Fireside chat:
Place:
Webcast Link:
Wednesday, June 3, 2026
10:30 a.m. ET
Marriott Marquis, New York, NY
Here

Goldman Sachs 47th Annual Global Healthcare Conference
Date:
Place:
Monday, June 8, 2026
Loews Miami Beach, Miami Beach, Fla.

Investors interested in arranging a meeting with the Company’s management during these conferences should contact the respective conference coordinators.

A live audio webcast of the Jefferies Global Healthcare Conference can also be accessed on the Events & Presentations section of the Supernus Pharmaceuticals website at www.supernus.com. Archived replays of the webcast will be available for 60 days on the Company’s website following the conference.

(Press release, Supernus, MAY 27, 2026, View Source [SID1234666103])

Sana Biotechnology to Present at June 2026 Investor Conferences

On May 27, 2026 Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, reported that it will webcast its presentations at two investor conferences in June. The presentations will feature a business overview and update.

Sana will present at the Jefferies Global Healthcare Conference at 9:20 a.m. ET on Wednesday, June 3, 2026.
Sana will present at the Goldman Sachs 47th Annual Global Healthcare Conference at 4:00 p.m. ET on Tuesday, June 9, 2026.
The webcasts will be accessible on the Investor Relations page of Sana’s website at View Source A replay of each presentation will be available at the same location for 30 days following the conference.

(Press release, Sana Biotechnology, MAY 27, 2026, View Source [SID1234666102])

Rigel to Present at the Jefferies Global Healthcare Conference

On May 27, 2026 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, reported that Raul Rodriguez, the company’s president and CEO, will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 8:45 a.m. ET in New York, NY.

To access the live webcast or archived recording, visit the Investor Relations section of the company’s website at www.rigel.com. Please connect to Rigel’s website prior to the start of the live webcast to allow for any software downloads.

(Press release, Rigel, MAY 27, 2026, View Source [SID1234666101])

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

On May 27, 2026 ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, reported that management will be participating in the following investor conferences in June:

Jefferies Global Healthcare Conference – Participating in a fireside chat on Wednesday, June 3, 2026, at 11:40 a.m. ET. Management will also be participating in one-on-one meetings.
Goldman Sachs 47th Annual Global Healthcare Conference – Participating in a fireside chat on Tuesday, June 9, 2026, at 8:00 a.m. ET. Management will also be participating in one-on-one meetings.

Webcasts of the fireside chat discussions will be available through the investor section of the company’s website at www.oricpharma.com. Replays of the webcasts will be available for 90 days following the event.

(Press release, ORIC Pharmaceuticals, MAY 27, 2026, View Source [SID1234666100])

NUCLIDIUM Announces Closing of Series B Extension Bringing Total Round to CHF 105 Million

On May 27, 2026 NUCLIDIUM AG, a clinical-stage radiopharmaceutical company, reported the closing of an oversubscribed CHF 26 million (EUR 28.4 million) Series B extension, bringing the Series B total raised to CHF 105 million (approximately EUR 115 million). The financing was led by existing investors Kurma Growth Opportunities Fund, Angelini Ventures, together with EIB co-investment facility Aurea, Wellington Partners and Neva SGR (Intesa Sanpaolo Group), with participation from DeepTech & Climate Fonds (DTCF), Bayern Kapital, Vives Partners, NRW.BANK, and additional existing investors.

„Emerging data from our Phase 1/2 diagnostics studies continue to generate strong momentum for NUCLIDIUM’S true radiotheranostics approach. We will build on our programs‘ best-in-class potential by initiating Phase 1/2a therapeutic studies for NU-101 and NU-201 later this year, demonstrating our direct conversion strategy from diagnosis to treatment. The Series B extension and support from our world-class investors further validate our strategy to advance next-generation copper-based radiotheranostics and unlock the full potential of the theranostic modality," said Leila Jaafar, PhD, CEO and Co-Founder of NUCLIDIUM .

Proceeds from the Series B extension will accelerate and expand the clinical development of NUCLIDIUM’S lead theranostic programs, NU101 in metastatic castration resistant prostate cancer (mCRPC) and NU201 in metastatic breast cancer (mBC), into advanced clinical trials. The financing will also support the continued buildout of its worldwide production and manufacturing network for diagnostics and therapeutics and expand novel target development for its preclinical programs to bring radiotheranostics to novel solid tumor indications.

„Radiopharmaceuticals are one of the most compelling growth opportunities in oncology today. NUCLIDIUM has established clear differentiation with its copper-based radiotheranostic approach, demonstrating clinical superiority to competing radioligands and ease-of-use that supports seamless integration into hospital workflow. We are proud to support NUCLIDIUM through this new phase of growth as it advances its pipeline toward additional clinical proof-of-concept data," said Regina Hodits, PhD, Managing Director at Angelini Ventures , Daniel Parera, MD, Partner at Kurma Partners and Mario Costantini, CEO and General Manager at Neva SGR (Intesa Sanpaolo Group) for all participating investors.

The Series B financing transaction was advised by VISCHER AG as legal counsel.

(Press release, NUCLIDIUM, MAY 27, 2026, View Source [SID1234666099])